A nitroindanedione mast cell stabiliser in the treatment of ulcerative colitis: a controlled trial.
An orally absorbed mast cell stabiliser (BRL-10833) has been compared with placebo in a double-blind controlled trial in twenty-five patients with ulcerative colitis; patients received each treatment for one month. There was no significant clinical improvement in symptoms or sigmoidoscopic findings with the drug but there was significant improvement in the histological appearance of rectal biopsies during active treatment.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000473:pathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007189:Indans / Q000008:administration & dosage*; D007192:Indenes / Q000008:administration & dosage*; D008297:Male; D008407:Mast Cells / Q000378:metabolism*; D008875:Middle Aged; D010919:Placebos
D007189:Indans; D007192:Indenes; D010919:Placebos